<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365273</url>
  </required_header>
  <id_info>
    <org_study_id>MPTO 04</org_study_id>
    <nct_id>NCT01365273</nct_id>
  </id_info>
  <brief_title>Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts</brief_title>
  <official_title>Open, Prospective, Randomised Investigation Evaluating Pain With the Use of Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation is an open, randomised investigation. Approximately 40 subjects in 4-5
      centres in the US with deep-partial of full thickness burns in need of skin grafts will be
      enrolled.The subjects will be equally randomised to either treatment with Mepitel One or
      bridal veil together with staples.

      The primary objective is to compare pain at the time of dressing change for the use of
      Mepitel One versus bridal veil together with staples on deep partial or full thickness burns
      requiring skin grafts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skin grafts are placed over excised areas of full thickness injuries and usually attached
      with sutures or staples. While useful in anchoring the graft in place, subjects often
      complain of pain from the staples as wound healing progresses.Pulling and sticking are common
      complaints.There is also a possibility that staples become embedded in the graft which leads
      to disruption of otherwise healed area, increased pain and anxiety for the subject as well as
      anxiety for the staff.

      Graft take can be optimized with appropriate medical management. Use of non-adherent
      dressings to protect the graft is customary. Various types of netting-style are used, such as
      Bridal veil, a sterile product which is fixed over the graft with staples.

      Silicone net dressings have also been used successfully to prevent lifting and adherence of
      skin grafts to the dressings, prevent pain and promote healing. Mepitel One is a sterile,
      transparent, and flexible wound contact layer consisting of perforated polyurethane film
      coated with Safetac soft silicone adhesive on one side. Mepitel One is available in various
      sizes and can be left in place for several days depending on the wound/skin condition.

      Evaluation of burns will be performed at Baseline. Skin graft assessment will be performed at
      Day 7 and Day 14. End of study will be considered the time that graft is considered to have
      &gt;95% take.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Score for Pain Before Dressing Removal</measure>
    <time_frame>At visit 6, day 7</time_frame>
    <description>Pain was measured with Visual Analogue Scale (VAS)(100 mm) measuring from 0 = &quot;no pain&quot; at one end to 100 = &quot;most intense pain imagaginable&quot; at the other end.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS Score for Pain During Dressing Removal</measure>
    <time_frame>Visit 6, day 7</time_frame>
    <description>Pain when half of the study product(s) has been removed measued with Visual Analogue Scale (VAS).0 = &quot;no pain&quot; till 100 = &quot;worst pain&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS Score for Pain After Dressing Removal</measure>
    <time_frame>Visit 6, day 7</time_frame>
    <description>Pain after the dressing removal measued with Visual Analogue Scale (VAS).0 = &quot;no pain&quot; till 100 = &quot;worst pain&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Deep Partial Thickness Burn</condition>
  <condition>Full Thickness Burns</condition>
  <arm_group>
    <arm_group_label>Bridal Veil together with staples</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care. Bridal Veil is fixed over the graft with staples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepitel One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device, dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepitel One</intervention_name>
    <description>Dressing</description>
    <arm_group_label>Mepitel One</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria

               1. Subjects presenting with 1% - 25% Total Body Surface Area (TBSA) deep partial or
                  full-thickness burns requiring skin graft

               2. At least 1%-10% TBSA is available for grafting that can be considered for study
                  site selection (must have intact, healthy peri-wound area around entire portion
                  of this burned site)

               3. Both genders with age â‰¥18 years but &lt; 70 years

               4. Signed informed consent

        Exclusion Criteria:

          1. Subjects with chronic wounds

          2. Subjects who are on mechanical ventilation

          3. Subjects with dermatologic skin conditions or necrotizing disorders

          4. Diagnosed underlying disease(s) (HIV/AIDS, cancer and severe anaemia)judged by the
             investigator to be a potential interference in the treatment

          5. Subjects treated with systemic glucocorticosteroids, except subjects taking occasional
             doses or doses less than 10 mg prednisolon/day or equivalent

          6. Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days

          7. Known allergy/hypersensitivity to any of the components of the investigational
             products

          8. Subjects with physical and/or mental conditions that are not expected to comply with
             the investigation

          9. Participation in other clinical investigation(s) within 1 month prior to start of the
             investigation

         10. Previously randomised to this investigation

         11. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Lou Patton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Speare Regional Burn Treatment Ctr. Croer Chester Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Foundation for Education &amp; Research, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph M. Still Research Foundation, Inc.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5028 Delp Bldg, Mail stop 1011</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natham Speare Regional Burn Treatment Ctr., Crozer Chester Medical Center</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <results_first_submitted>May 2, 2012</results_first_submitted>
  <results_first_submitted_qc>August 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Split thickness skin grafts</keyword>
  <keyword>Mepitel One</keyword>
  <keyword>Bridal Veil and staples</keyword>
  <keyword>Pain</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first patient included: 26 April 2011 Date of last patient completed: 01 December 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bridal Veil and Staples</title>
          <description>Bridal Veil and staples are standard of care I</description>
        </group>
        <group group_id="P2">
          <title>Mepitel One</title>
          <description>Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Compl. Pts, Not Evaluable for Pain.</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bridal Veil and Staples</title>
          <description>Bridal Veil and staples are standard of care I</description>
        </group>
        <group group_id="B2">
          <title>Mepitel One</title>
          <description>Device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="16.0"/>
                    <measurement group_id="B2" value="38.0" spread="18.0"/>
                    <measurement group_id="B3" value="40.15" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS Score for Pain Before Dressing Removal</title>
        <description>Pain was measured with Visual Analogue Scale (VAS)(100 mm) measuring from 0 = &quot;no pain&quot; at one end to 100 = &quot;most intense pain imagaginable&quot; at the other end.</description>
        <time_frame>At visit 6, day 7</time_frame>
        <population>All subjects to post-randomization treatment and that provided some data for the primary endpoint were included in the ITT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bridal Veil and Staples</title>
            <description>Bridal Veil and staples are standard of care I</description>
          </group>
          <group group_id="O2">
            <title>Mepitel One</title>
            <description>Device</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score for Pain Before Dressing Removal</title>
          <description>Pain was measured with Visual Analogue Scale (VAS)(100 mm) measuring from 0 = &quot;no pain&quot; at one end to 100 = &quot;most intense pain imagaginable&quot; at the other end.</description>
          <population>All subjects to post-randomization treatment and that provided some data for the primary endpoint were included in the ITT analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="21.0"/>
                    <measurement group_id="O2" value="4.0" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VAS Score for Pain During Dressing Removal</title>
        <description>Pain when half of the study product(s) has been removed measued with Visual Analogue Scale (VAS).0 = &quot;no pain&quot; till 100 = &quot;worst pain&quot;.</description>
        <time_frame>Visit 6, day 7</time_frame>
        <population>All included subjects to post-randomization treatment and that provided some data for the primary endpoint was included in the Intention To Treat analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Bridal Veil and Staples</title>
            <description>Bridal Veil and staples are standard of care I</description>
          </group>
          <group group_id="O2">
            <title>Mepitel One</title>
            <description>Device</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score for Pain During Dressing Removal</title>
          <description>Pain when half of the study product(s) has been removed measued with Visual Analogue Scale (VAS).0 = &quot;no pain&quot; till 100 = &quot;worst pain&quot;.</description>
          <population>All included subjects to post-randomization treatment and that provided some data for the primary endpoint was included in the Intention To Treat analyses.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="28.6"/>
                    <measurement group_id="O2" value="4.0" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VAS Score for Pain After Dressing Removal</title>
        <description>Pain after the dressing removal measued with Visual Analogue Scale (VAS).0 = &quot;no pain&quot; till 100 = &quot;worst pain&quot;.</description>
        <time_frame>Visit 6, day 7</time_frame>
        <population>All subjects to post-randomization treatment and that provided some data for the primary endpoint were included in the ITT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bridal Veil and Staples</title>
            <description>Bridal Veil and staples are standard of care I</description>
          </group>
          <group group_id="O2">
            <title>Mepitel One</title>
            <description>Device</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score for Pain After Dressing Removal</title>
          <description>Pain after the dressing removal measued with Visual Analogue Scale (VAS).0 = &quot;no pain&quot; till 100 = &quot;worst pain&quot;.</description>
          <population>All subjects to post-randomization treatment and that provided some data for the primary endpoint were included in the ITT analysis.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="34.7"/>
                    <measurement group_id="O2" value="3.0" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bridal Veil and Staples</title>
          <description>Bridal Veil and staples are standard of care I</description>
        </group>
        <group group_id="E2">
          <title>Mepitel One</title>
          <description>Device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor is the owner of the results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joan Wilson, MSN, MHA, RN</name_or_title>
      <organization>Monlycke Health Care</organization>
      <phone>706 504 8997</phone>
      <email>joan.wilson@molnlycke.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

